Effects of SGLT2 inhibitor on hemodynamic parameters, target organ damage and obesity profile in resistant hypertensive subjects

• Grant number: 16/00483-0
• Support Opportunities: Regular Research Grants
• Start date: July 01, 2016
• End date: January 31, 2018
• Field of knowledge: Biological Sciences - Pharmacology - Clinical Pharmacology
• Principal Investigator: Rodrigo Gimenez Pissutti Modolo
• Grantee: Rodrigo Gimenez Pissutti Modolo
• Host Institution: Hospital de Clínicas (HC). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil
• City of the host institution: Campinas
• Associated researchers: Alessandra Mileni Versuti Ritter ; Ana Paula Cabral de Faria Modolo ; Heitor Moreno Junior

Abstract

This crossover randomized, double-blind, interventional study controlled by standard therapy aims to assess whether the intervention with the SGLT2 inhibitor -dapaglifozin - reduces PA levels, target organ damage, fat profile and change the adipokines levels in patients with resistant hypertension with DM2. We will include 20 patients with resistant hypertension and type 2 diabetes, followed in Outpatient Clinic specialized in Resistant Hypertension at clinical Hospital-UNICAMP. They will be randomly assigned into two groups (1) initially treated with dapagliflozin in combination with their usual antihypertensive therapy and metformin, at 12 weeks (n = 10) or group (2) Control initially treated with glibenclamide at a dose of 5mg daily in combination with antihypertensive therapy usual and metformin, at 12 weeks (n = 10). Office ambulatory and home BP measurements; anthropometric measurements, determination of vascular stiffness by pulse wave velocity, echocardiogram, body bioimpedance, enzyme immunoassays for the determination of adipokines, and lab tests to evaluate biochemical parameters will be performed pre- and after the use of both treatments. Glycemic parameters, and weight will be assessed every 4 weeks. The use of SGLT2 inhibitor in these patients may provide new strategies for treatment of patients with resistant hypertension. (AU)